01 / AI · Analysis
MSD declines Ingenia's IGT-302 glaucoma option as rights end
The glaucoma option under a separate agreement has ended, but the disclosure as reported gives no reason why MSD did not exercise it

Ingenia Therapeutics, a South Korean biotechnology company, received notice that MSD (Merck & Co.) will not exercise its glaucoma option on IGT-302, Ingenia said in a disclosure on 9 Nov 2026, South Korean news outlet Digital Today reported. The disclosure describes the matter as the end of the option for the glaucoma indication.
An indication is the disease a treatment is meant to target. An option is a right, set out in an agreement, that a party can choose whether to exercise. The notice concerns the research and development agreement on IGT-302 for glaucoma, Digital Today reported, and the central point of the disclosure is that the partner's option closed without being exercised.
The disclosure is best read through its dates and the structure of the agreement.
MSD's notice arrived on 7 Nov 2026
The disclosure lists both the date of occurrence, or confirmation, and the decision date as 7 Nov 2026, according to the report.
Digital Today reported that this is the date on which Ingenia was notified by MSD, and that it is stated in Korea time. The disclosure followed on 9 Nov 2026.
The option rests on a separate glaucoma agreement
The glaucoma option rests on a research agreement signed separately on 31 Oct 2022, according to the report. MSD's reason for not exercising the option does not appear in the disclosure as reported.
On the disclosure as Digital Today reported it, the option that has ended is the one for glaucoma. It closed unexercised under the separate research agreement that provided for it.